Followers | 123 |
Posts | 16771 |
Boards Moderated | 1 |
Alias Born | 07/21/2006 |
Wednesday, May 12, 2021 4:13:51 PM
Recent SNDX News
- Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/13/2025 12:00:00 PM
- Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm • PR Newswire (US) • 01/08/2025 02:20:00 AM
- Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/07/2025 12:00:00 PM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 01/03/2025 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2024 10:00:08 PM
- Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial • PR Newswire (US) • 12/09/2024 12:30:00 PM
- Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting • PR Newswire (US) • 12/07/2024 11:15:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 12/06/2024 09:28:33 PM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 12/03/2024 09:05:00 PM
- Syndax Announces Participation at the Citi 2024 Global Healthcare Conference • PR Newswire (US) • 11/27/2024 12:00:00 PM
- Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation • PR Newswire (US) • 11/15/2024 10:29:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 12:05:36 PM
- Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib • PR Newswire (US) • 11/12/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2024 09:03:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2024 09:02:08 PM
- Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 11/05/2024 09:01:00 PM
- Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 • PR Newswire (US) • 11/05/2024 02:01:00 PM
- Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting • PR Newswire (US) • 11/05/2024 02:00:00 PM
- Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting • PR Newswire (US) • 11/05/2024 02:00:00 PM
- Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ • PR Newswire (US) • 11/04/2024 09:01:00 PM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 11/01/2024 08:05:00 PM
- Syndax Announces Participation in November Investor Conferences • PR Newswire (US) • 11/01/2024 11:00:00 AM
- Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024 • PR Newswire (US) • 10/29/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 10/04/2024 08:05:00 PM
UAV Corp Skyborne Technology Secures $105M in Sales Contract LOIs for Revolutionary DART Series Airships • UMAV • Jan 13, 2025 11:00 AM
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024) • SNWV • Jan 13, 2025 8:10 AM
SANUWAVE Health Appoints Industry Veteran Timothy Wern as Executive Vice President of Sales • SNWV • Jan 13, 2025 8:08 AM
North Bay Resources Announces Operation of New Gravity Circuit at Bishop Gold Mill, California • NBRI • Jan 10, 2025 8:29 AM
Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology • BLO • Jan 9, 2025 8:49 AM
UAV Corp. (UMAV) Further Reduces Authorized Shares to 500 Million • UMAV • Jan 8, 2025 2:27 PM